Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;8(1):59-75.
doi: 10.15171/bi.2018.08. Epub 2018 Feb 25.

Combating Atherosclerosis With Targeted Nanomedicines: Recent Advances and Future Prospective

Affiliations
Free PMC article
Review

Combating Atherosclerosis With Targeted Nanomedicines: Recent Advances and Future Prospective

Ailar Nakhlband et al. Bioimpacts. .
Free PMC article

Abstract

Introduction: Cardiovascular diseases (CVDs) is recognized as the leading cause of mortality worldwide. The increasing prevalence of such disease demands novel therapeutic and diagnostic approaches to overcome associated clinical/social issues. Recent advances in nanotechnology and biological sciences have provided intriguing insights to employ targeted Nanomachines to the desired location as imaging, diagnosis, and therapeutic modalities. Nanomedicines as novel tools for enhanced drug delivery, imaging, and diagnosis strategies have shown great promise to combat cardiovascular diseases. Methods: In the current study, we intend to review the most recent studies on the nano-based strategies for improved management of CVDs. Results: A cascade of events results in the formation of atheromatous plaque and arterial stenosis. Furthermore, recent studies have shown that nanomedicines have displayed unique functionalities and provided de novo applications in the diagnosis and treatment of atherosclerosis. Conclusion: Despite some limitations, nanomedicines hold considerable potential in the prevention, diagnosis, and treatment of various ailments including atherosclerosis. Fewer side effects, amenable physicochemical properties and multi-potential application of such nano-systems are recognized through various investigations. Therefore, it is strongly believed that with targeted drug delivery to atherosclerotic lesions and plaque, management of onset and progression of disease would be more efficient than classical treatment modalities.

Keywords: Atherosclerosis; Cardiovascular diseases; Drug delivery; Drug targeting; Nanomedicines.

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. JCvD. 2013;1:1–2.
    1. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. WHO; 2011.
    1. Lee JT, Lawson KD, Wan Y, Majeed A, Morris S, Soljak M. et al. Are cardiovascular disease risk assessment and management programmes cost effective? A systematic review of the evidence. Prev Med. 2017;99:49–57. doi: 10.1016/j.ypmed.2017.01.005. - DOI - PubMed
    1. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197–207. doi: 10.1016/j.ehj.2004.03.011. - DOI - PubMed
    1. Psarros C, Lee R, Margaritis M, Antoniades C. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Maturitas. 2012;73:52–60. doi: 10.1016/j.maturitas.2011.12.014. - DOI - PubMed

LinkOut - more resources

Feedback